secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atrium Therapeutics, Inc. (RNA)
CIK:        0002093101
Form:       8-K
Filed at:   2026-05-14T20:50:07+00:00
Accession:  0001193125-26-224238
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M
--------------------------------------------------------------------------------

- Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.
- R&D expenses $16.7M, G&A $20.3M; cash and equivalents $267.8M.
- ATR 1072 IND submission planned for H2 2026; pre-IND discussions with FDA/Health Canada completed.
- Company launched as independent public on Feb 27, 2026 after spin-off from Avidity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/0001193125-26-224238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/d82207d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer